Status:
COMPLETED
New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)
Lead Sponsor:
Norwegian University of Science and Technology
Collaborating Sponsors:
Akershus Dermatological Centre
Helse Stavanger HF
Conditions:
Skin Neoplasms
Carcinoma, Basal Cell
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Basal cell carcinoma (BCC) is the most common malignant skin lesion in white adults. It is a slow-growing tumour which despite low metastatic potential may cause significant local tissue destruction a...
Eligibility Criteria
Inclusion
- male/female above 18 years of age
- written informed consent
- 1 or more primary histologically verified BCC, clinically assessed as of either superficial of nodular type
Exclusion
- pregnancy
- breastfeeding
- Gorlin's syndrome
- porphyria
- xeroderma pigmentosum
- history of arsenic exposure
- known allergy to MAL
- concomitant treatment with immunosuppressive medication
- physical or mental conditions that most likely will prevent patients attending follow-up sessions
Key Trial Info
Start Date :
June 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2017
Estimated Enrollment :
277 Patients enrolled
Trial Details
Trial ID
NCT01482104
Start Date
June 1 2012
End Date
October 1 2017
Last Update
October 27 2017
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept Dermatology, Haukeland University Hospital
Bergen, Norway
2
Central Hospital Førde
Førde, Norway
3
Hudlegekontoret Lillehammer AS
Lillehammer, Norway
4
Akerskus Dermatological Centre
Lørenskog, Norway